Sector News

In regional shakeup, Novartis’ Alcon fires two Asia execs

June 12, 2015
Life sciences
Two key executives of Novartis subsidiary Alcon with responsibility for Asia were fired this week, AsianScientist reported, after confirming the action by the parent company.
 
Roy Acosta, Asia & Russia region president, and Jim West, Asia & Russia chief financial officer, of global medical company Alcon were fired on June 10, AsianScientist said, noting that Novartis declined to discuss the reasons for the move.
 
In an email response, Novartis confirmed to FiercePharmaAsia that the two executives had left the company.
 
“Novartis can confirm that Roy Acosta, Region President, Asia & Russia, and Jim West, Chief Financial Officer, Asia & Russia, will be leaving the company after 25 years of service, respectively,” a company spokesman said in an email.
 
Eric Van Oppens, who is currently head of the Asia cluster for Novartis Pharma, will replace Acosta as Asia & Russia region president at Alcon, effective July 1, the spokesperson said.
 
Oppens, who is currently head of the Asia Cluster for Novartis Pharma, has been appointed as region president, Asia & Russia at Alcon, effective July 1.
 
Acosta reported directly to Jeff George, head of Alcon and member of the executive committee of Swiss-based Novartis.
 
Alcon, which makes sterile eye care products and operates out of Fort Worth, Texas, is the second-largest division of Novartis; it was bought in 2011 for $51.9 billion.
 
AsianScientist said that Acosta joined Alcon in 1989 and has held various leadership positions within U.S. and International Operations, citing his biography on the company’s website.
 
Alcon faced accusations in 2013 of diverting funds meant for postmarketing surveys to bribe doctors in China.
 
Novartis faced sales sanctions and investigations by regulators last year in Japan over failure to report serious side effects during clinical trials as well as complaints that sales officials had an indirect role in managing data.
 
AsianScientist said a spokesperson for Novartis Media Relations in Basel confirmed that Acosta and West were let go on Wednesday.
 
By EJ Lane
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”